An interventional study of Video & movements recording and Questionnaires in Autism Spectrum Disorder, sponsored by Centre Hospitalier Charles Perrens, Bordeaux. Recruiting at 1 site in France. Open to participants aged 6 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-16.
Sponsored by Centre Hospitalier Charles Perrens, Bordeaux · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies in Autism Spectrum Disorder with a site in France — 51 open to participants now, 55 under way, 2 of them phase 3. Autism Spectrum Disorder · France.
Among the 110 studies in Autism Spectrum Disorder with a site in France, this one is the 21st largest by planned enrollment of the 77 interventional ones that give a count, is one of 7 that started in 2021, is one of 58 with no phase, reaches primary completion later than 17 of the 54 other live ones, and was the 47th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →51 of the 110 studies in Autism Spectrum Disorder with a site in France are open now. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in France, United States, Germany and 7 more countries
Ages 5–17
Hopital La Musse · Sites in France
Ages 15–17 · Healthy volunteers
Hospices Civils de Lyon · Sites in France
Ages 5–50
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 8–16
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 6 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 12 · Phase 3 9
First in 2007; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is above the median of 52 across 1,374 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 70 across the 77 interventional studies, 120 across the 33 observational. Of the 43 that completed or were terminated, 8 (19%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 110 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Charles Perrens, Bordeaux is the lead sponsor of 19 studies on the registry; 12 are open to participants now.
Centre Hospitalier Charles Perrens, Bordeaux has 2 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
17 of the studies in Autism Spectrum Disorder with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07655115Phase 3Hospital General Universitario Gregorio MarañonSingle Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th | 2026-12-31 |
| NCT06871696Institut National de la Santé Et de la Recherche Médicale, FranceGenetic of Intellectual Deficiency and Autism Spectrum Disorders (RaDiCo-GenIDA) | 2026-11 |
| NCT05512637University Hospital, MontpellierScreening for Neurodevelopmental Disorders in Siblings of Children With Autism Diagnosed in Tertiary Centers | 2026-11 |
| NCT04638452Centre Hospitalier Charles Perrens, BordeauxEvaluation of Behavioural Psycho & Physiological Responses in People With ASD During a Blood Test in Routine Care Practice | 2026-11-30 |
| NCT05864508University Hospital, ToulouseInterest of Oxytocin as an Adjuvant Treatment of Psycho-educational Measures in Challenging Behaviors in Children With Autism Spectrum Disorders and Moderate to Severe Intellectual Disability: Feasibility and Safety Study. | 2026-12 |
Add all 17 to your calendar (.ics) → With an account.
Among the 110 studies in Autism Spectrum Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project is a prospective study designed to characterize behaviour and its psycho-physiological correlates of participants with ASD (children and adults) in comparison with subjects without ASD matched in age during blood test in common practice.
The project is a prospective study designed to characterize behaviour and its psycho-physiological correlates of participants with ASD (children and adults) in comparison with subjects without ASD matched in age during blood test in common practice.
The aim is to analyse in an automated and standardised way video recording during a blood test performed as part of routine follow-up care for people presenting ASD (children and adults), qualitative data (type of emotion) and quantitative (intensity)
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All participants :
Participants with ASD :
Exclusion Criteria:
All participants :
Participants without ASD :
Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test Passing self and hetero questionnaires of temotion felt and perceived.
Behavioral: Video & movements recording · Behavioral: Questionnaires
Video recording of face, body movements and physiological parameters (heart rate, conductance using a wireless watch) of the participants during the blood test
Passing self and hetero questionnaires of emotion felt and perceived.
Facial expression during blood sample
Evaluation of facial expression during blood sample in people with ASD as compared to healthy people with Face reader, Noldus sofware.
Time frame: through study completion, an average of 1 to 6 months
Body movement during blood sample
Evaluation of body movement during blood sample in people with ASD as compared to healthy people with EMPATICA watch and Face, Legs, Activity, Cry, Consolabilty (FLACC) scale
Time frame: through study completion, an average of 1 to 6 months
Evaluation of emotion felt by participants during blood sample
Evaluation of emotion felt by participants (anxiety, stress, pain, apprehension…) during blood sample with implified Scale for Assessing Pain in Dyscommunicatives People with Autism Spectrum Disorders (ESSDA) and Pain Assessment Grid - Intellectual Disability (GEDDI) scales
Time frame: through study completion, an average of 1 to 6 months
Plan to share: No
Started Feb 2021 (actual). Primary completion is estimated for Nov 2026, 69 months after the start.
Of 806 non-industry interventional studies with no phase under Autism Spectrum Disorder, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 69 months is above that.
Counting every sponsor, half of 829 studies reached it within 25 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Charles Perrens, Bordeaux